Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Corporate Investor Presentation

Rigel Corporate Investor Presentation

Date	Title
08/06/19	Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update TAVALISSE® net product sales increased 26% quarter over quarter to $10.2 million First patients enrolled in Phase 3 pivotal trial of TAVALISSE in warm autoimmune hemolytic anemia (AIHA) Conference call and webcast today at 4:30PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug.
07/30/19	Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results SOUTH SAN FRANCISCO , July 30, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2019 financial results after market close on Tuesday, August 6 , 2019. Rigel senior management will follow the announcement with a live conference
06/13/19	Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA) SOUTH SAN FRANCISCO , June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters at the 24 th Congress of the European Hematology Association (EHA) in Amsterdam, The

Stock Quote

(Common Stock)
Exchange	(US Dollar)
Price
Change (%)
Volume
Data as of

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site

Investors

Investors

Corporate Profile

Corporate Investor Presentation

Stock Quote

Stock Chart

E-mail Alerts